10-Q: Athira Pharma Shifts Focus to ATH-1105 Amid Strategic Review

Athira Pharma reports reduced net loss and operating expenses in Q3 2025, driven by a strategic shift to ATH-1105 development and a workforce reduction, while exploring strategic alternatives.

Summary

• Net loss significantly decreased to $22.7 million for the nine months ended September 30, 2025, compared to $81.9 million for the same period in 2024.
• Cash used in operations improved to $26.3 million for the nine months ended September 30, 2025, from $71.2 million in the prior year.
• Research and development expenses decreased by $50.5 million, from $61.3 million in 2024 to $10.8 million in 2025, primarily due to pausing fosgonimeton development.
• General and administrative expenses decreased by $7.0 million to $12.9 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and investments totaled $25.2 million as of September 30, 2025, estimated to fund operations for at least the next 12 months.
• The company is actively exploring strategic alternatives, including potential mergers, acquisitions, or financing, to maximize stockholder value.
• Development of fosgonimeton has been paused following unsuccessful Phase 2/3 LIFT-AD trial results, with focus shifting to ATH-1105.
• ATH-1105, a lead drug candidate for neurodegenerative diseases, completed a Phase 1 trial with a favorable safety profile and is preparing for a future clinical trial in ALS patients.
• A 1-for-10 reverse stock split was effected on September 17, 2025, and the company regained Nasdaq compliance on October 2, 2025.

Sentiment

Score: 5

Explanation: While the financial performance shows significant improvement in reducing losses and cash burn, this is largely due to the discontinuation of a failed lead program (fosgonimeton) and a substantial workforce reduction. The company is now heavily reliant on ATH-1105, which is still in early clinical development, and is actively seeking strategic alternatives, indicating a period of uncertainty and potential significant changes. The improved financial metrics are a result of cost-cutting rather than revenue generation or clinical success of a late-stage asset.

Positives

• Significant reduction in net loss for the nine months ended September 30, 2025, to $22.7 million from $81.9 million in the prior year.
• Substantial decrease in cash used in operating activities, from $71.2 million in 2024 to $26.3 million in 2025.
• Research and development expenses decreased by 82% due to strategic reprioritization.
• ATH-1105, the new lead drug candidate, demonstrated a favorable safety profile and was well-tolerated in its Phase 1 clinical trial.
• The company successfully regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.
• Current cash, cash equivalents, and investments of $25.2 million are estimated to fund operations for at least the next 12 months.

Negatives

• Fosgonimeton, the previous lead drug candidate, failed to meet primary and key secondary endpoints in its Phase 2/3 LIFT-AD clinical trial, leading to a pause in its development.
• The company has incurred significant losses since inception, with an accumulated deficit of $428.9 million as of September 30, 2025.
• Total stockholders' equity decreased from $44.8 million at December 31, 2024, to $26.8 million at September 30, 2025.
• Other income, net, decreased by $2.4 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• The company will require substantial additional funding beyond the next 12 months to complete development and commercialization of drug candidates.
• The market capitalization is currently below the value of current cash, cash equivalents, and short-term investments, indicating potential undervaluation or market skepticism.

Risks

• Limited operating history as a clinical-stage biopharmaceutical company, making future success and viability uncertain.
• Development of ATH-1105 may never lead to a marketable product, and future trials may not yield data supporting safety, efficacy, and tolerability.
• The novel therapeutic approach targeting neurotrophic factors through small molecules exposes the company to unforeseen risks and uncertain outcomes.
• Clinical development is a lengthy, expensive, and uncertain process, with early-stage results not predictive of later-stage success, potentially leading to substantial delays or failures.
• Risk of expending limited resources on drug candidates or indications that ultimately fail or are less profitable.
• Potential for claims, lawsuits, government investigations, and securities class action litigation, which could divert management's attention and incur substantial costs.
• Topline, interim, or preliminary clinical trial data may change upon comprehensive review, leading to material changes in final data.
• Delays in reporting clinical trial data or obtaining regulatory approvals could occur.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, incur debt, or assume contingent liabilities.
• Substantial additional funding will be required to finance operations, complete development, and commercialization of ATH-1105 and other current and potential drug candidates.
• Inability to protect intellectual property and proprietary technologies could adversely affect the ability to prevent competitors from commercializing similar products.
• Significant competition from larger, better-resourced pharmaceutical and biotechnology companies.
• Loss of key personnel could significantly harm the business.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable, with potential for delays or denial of approval.
• Reliance on third parties to conduct nonclinical studies and clinical trials, and for manufacturing, poses risks of non-compliance, delays, or insufficient quantities.
• Even if approved, drug candidates may not achieve adequate market acceptance or reimbursement.
• Lack of prior experience in commercializing a drug candidate.
• Volatility in the market price of common stock.
• Actions by activist stockholders could be disruptive and cause uncertainty.
• Potential for significant adverse events or undesirable side effects from drug candidates.
• Difficulty in obtaining and maintaining regulatory approval across different jurisdictions.
• Ongoing regulatory obligations and review post-approval, with potential for penalties for non-compliance.
• Potential difficulties from changes to current healthcare regulations and future legislation, including cost containment measures.
• Exposure to federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws.
• Dependence on networks, infrastructure, and data, exposing the company to cybersecurity risks.
• Potential for the board of directors to pursue dissolution and liquidation, impacting stockholder distributions.
• Patent terms may be inadequate to protect competitive position on drug candidates for an adequate amount of time.
• Geopolitical actions could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents.
• Risk of claims challenging inventorship or ownership of patents and other intellectual property.
• Reliance on third-party licenses, with risks of losing rights or disputes.
• Intellectual property discovered or developed through government-funded programs may be subject to federal regulations such as march-in rights.
• Data collection is governed by restrictive regulations (GDPR, CCPA, etc.), increasing compliance burdens and potential liabilities.
• Reverse stock split to regain Nasdaq compliance may not result in a lasting proportional increase in the per share price of common stock and may decrease its liquidity.
• Failure to build and maintain finance infrastructure and improve accounting systems and controls could impair compliance with financial reporting requirements.
• Anti-takeover provisions in charter documents and under Delaware or Washington law could make an acquisition of the company difficult, limit attempts by stockholders to replace or remove current management, and limit stock price.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum for disputes with the company or its directors, officers or employees.
• The potential effects of health epidemics could adversely impact the business, including nonclinical studies and clinical trials.

Future Outlook

The company estimates its existing cash, cash equivalents, and investments of $25.2 million as of September 30, 2025, will be sufficient to fund operating expenses and capital expenditure requirements through at least the next 12 months. It expects to continue incurring operating losses and will require substantial additional funding to complete the development and commercialization of ATH-1105 and other drug candidates, potentially through equity sales, debt financings, or strategic collaborations. Research and development expenses are expected to remain lower in the near term due to the pause in fosgonimeton development and the recent workforce reduction.

Management Comments

• We are actively reviewing options for partnerships or other arrangements that will allow us to realize the potential of our drug candidates.
• Based on these results [LIFT-AD], we decided to pause further development of fosgonimeton and to shift our focus to the clinical development of ATH-1105.
• The results of the Phase 1 trial showed that ATH-1105 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers, supporting continued clinical development.
• Despite devoting significant effort to identifying and evaluating potential strategic alternatives, there can be no assurance that this strategic review process will result in us pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all.
• Based upon our current operating plan, we estimate that our $25.2 million of cash, cash equivalents and investments at September 30, 2025 will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.

Industry Context

The company operates in the highly competitive and rapidly advancing biotechnology and pharmaceutical industries, specifically focusing on central and peripheral nervous system degenerative disorders, a field with historically limited success in product development. The shift from fosgonimeton to ATH-1105 reflects the inherent risks and uncertainties of drug development, where early-stage results do not guarantee later-stage success. The exploration of strategic alternatives is a common response for clinical-stage companies facing significant funding needs and clinical trial setbacks, especially in a volatile economic environment with increasing scrutiny on drug pricing and regulatory pathways.

Comparison to Industry Standards

• The company's focus on CNS and PNS degenerative disorders is in a field that has seen very limited success in product development, indicating a higher risk profile compared to less challenging therapeutic areas.
• The failure of fosgonimeton's Phase 2/3 LIFT-AD trial to meet primary and key secondary endpoints is consistent with the high attrition rate in biopharmaceutical development, where most product candidates fail to reach approval despite promising early results.
• The company's reliance on third-party CMOs and CROs is a standard industry practice for clinical-stage biopharmaceutical companies that lack internal manufacturing and extensive clinical trial infrastructure.
• The exploration of strategic alternatives (merger, acquisition, financing) is a common strategy for biotech companies, especially those with a market capitalization below their cash value, to maximize stockholder value or secure necessary funding.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation-related accruals recorded as of September 30, 2025.
• The company is not a party to any legal proceedings that would reasonably be expected to have a material adverse effect on its business, financial condition, operating results, or cash flows.
• Washington State University (WSU) undertook a review of prior claims of potential research misconduct involving the company's former chief executive officer's doctoral research at WSU. The company cannot predict the effect of this review on its business and reputation.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; uncertainty regarding strategic alternatives; impact of reverse stock split on share price and liquidity; potential for substantial losses due to stock volatility and clinical trial risks.
• Employees: Significant workforce reduction (70% in 2024) may impact morale and future recruiting efforts; stock-based compensation plans are in place to attract and retain personnel.
• Customers (future): Development of ATH-1105 aims to address neurodegenerative diseases like ALS, AD, and PD, potentially offering new therapeutic options.
• Suppliers/CROs/CMOs: Continued reliance on third-party contractors for R&D and manufacturing, implying ongoing business for these partners, but also risks if they fail to perform.
• Creditors: The company's need for substantial additional funding and accumulated deficit indicate a higher risk profile for creditors, though current cash is sufficient for 12 months.

Next Steps

• Initiate a future clinical trial for ATH-1105 in people living with ALS, either independently or in conjunction with a partner.
• Continue to explore strategic alternatives focused on maximizing stockholder value, potentially including an acquisition, merger, or financing.
• Optimize the manufacturing process for ATH-1105 to support future large-scale production.
• Build a commercial infrastructure or collaborate with pharmaceutical companies for commercialization if drug candidates are approved.
• Continue to invest in drug development programs and maintain the intellectual property portfolio.

Key Dates

Recommendation

Athira Pharma is in a transitional phase, having paused development of its previous lead candidate, fosgonimeton, due to unsuccessful trial results, and is now focusing on ATH-1105, which is in early clinical development. While the company has significantly reduced its cash burn and net losses through cost-cutting and a workforce reduction, and has sufficient cash for the next 12 months, its long-term viability hinges on the success of ATH-1105 and the outcome of its strategic review process. The exploration of strategic alternatives introduces both potential upside (e.g., a favorable acquisition or partnership) and downside (e.g., dissolution). Given the early stage of ATH-1105 and the inherent uncertainties of the strategic review, a 'hold' recommendation is appropriate. Investors should monitor the progress of ATH-1105's clinical trials and the developments from the strategic review before making further investment decisions.

Keywords

Biopharmaceutical, Neurodegeneration, ATH-1105, ALS, Alzheimer's Disease, Parkinson's Disease, Clinical Stage, Small Molecule, HGF System, SEC Filing, 10-Q, Equity Incentive Plan, Stock Split, Strategic Alternatives, Drug Development, Biotech, Nasdaq Compliance, Financial Results